Barclays PLC cut its holdings in BioNTech SE (NASDAQ:BNTX – Free Report) by 37.7% during the 3rd quarter, Holdings Channel reports. The fund owned 83,253 shares of the company’s stock after selling 50,453 shares during the period. Barclays PLC’s holdings in BioNTech were worth $9,887,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the business. Candriam S.C.A. increased its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Fred Alger Management LLC purchased a new stake in BioNTech in the third quarter worth about $59,485,000. Baillie Gifford & Co. raised its stake in shares of BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after buying an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after buying an additional 7,340 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after buying an additional 74,119 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.
BioNTech Trading Down 5.1 %
BNTX stock opened at $114.22 on Tuesday. The firm has a fifty day moving average price of $113.72 and a 200 day moving average price of $100.54. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a market cap of $27.15 billion, a PE ratio of -54.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.
Analyst Ratings Changes
A number of equities research analysts have commented on the stock. Bank of America raised their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. HSBC increased their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, TD Cowen dropped their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $140.76.
BioNTech Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also
- Five stocks we like better than BioNTech
- Expert Stock Trading Psychology Tips
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- How to Calculate Inflation Rate
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Learn Technical Analysis Skills to Master the Stock Market
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTX – Free Report).
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.